Deferasirox

Data Sheet For research use only. Not for human use.

Cat. No. ：BCP05341CAS No. ：201530-41-8Purity：98%

Get Quotation Now

Tel: 0086-13026320035 or orders@biochempartner.com

* Required Fields.

Please complete the form below and you will get the price list in 1 minute.

* Required Fields.

Please complete the form below and we will contact you shortly.

* Required Fields.

Please complete the form below and we will contact you shortly.

Sci Rep. 2020; 10: 1577.

CAS No.	201530-41-8	Cat. No.	BCP05341
Name	Deferasirox
Synonyms	ICL670; IC-L670; ICL 670; ICL-670A; ICL670A; ICL 670A; CGP-72670; CGP72670;CGP 72670;
SMILES	C1=CC(=C2NC(=C3C=CC=CC3=O)N(N2)C4=CC=C(C=C4)C(=O)O)C(=O)C=C1
Chemical Name
Formula	C21H15N3O4	M. Wt	373.36
Purity	98%	Storage	Store at 4-8°C
Description	Deferasirox's main use is to reduce chronic iron overload in patients who are receiving long-term blood transfusions for conditions such as beta-thalassemia and other chronic anemias. Deferasirox is the first oral medication approved in the USA for this purpose. The half-life of deferasirox is between 8 and 16 hours allowing once a day dosing. Two molecules of deferasirox are capable of binding to 1 atom of iron which are subsequently eliminated by fecal excretion. Its low molecular weight and high lipophilicity allows the drug to be taken orally unlike desferoxamine which has to be administered by IV route (intravenous infusion). Together with deferiprone, deferasirox seems to be capable of removing iron from cells (cardiac myocytes and hepatocytes) as well as removing iron from the blood.